Skip to main content
Top
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Metastasis | Primary research

The E2F3/miR-125a/DKK3 regulatory axis promotes the development and progression of gastric cancer

Authors: Yihua Pei, Zhiteng Tang, Minjing Cai, Qin Yao, Bozhen Xie, Xin Zhang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Gastric cancer (GC) is one of the most common malignant tumours with high mortality and metastasis rates. E2F3, miR-125a and DKK3 have been reported to be involved in various cancer types, but their detailed roles in GC have not been fully understood.

Methods

A QRT-PCR assay was used to examine the expression of E2F3, miR-125a and DKK3 in metastatic and nonmetastatic GC tissues. DKK3 plasmids, DKK3 shRNA, miR-125a mimic and miR-125a inhibitor were transfected into BGC823 cells to evaluate the biological functions of DKK3 and miR-125a. A scratch wound healing assay and Transwell assay were utilized to determine the migratory and invasive ability of BGC823 cells transfected with the DKK3 plasmids, DKK3 shRNA, miR-125a mimic and miR-125a inhibitor. Moreover, qRT-PCR and WB analysis were used to analyse the mRNA and protein expression levels of metastasis-related genes after proper transfection. The target relationship between miR-125a and the DKK3 mRNA 3′UTR was determined by a dual luciferase reporter assay, while the interaction between E2F3 and miR-125a was analysed by a ChIP assay.

Results

The clinical data showed that the DKK3 expression level in metastatic GC samples was significantly less than that in nonmetastatic GC samples, whereas the E2F3 and miR-125a expression levels in metastatic GC samples were notably greater than those in nonmetastatic GC samples. Moreover, knockdown of DKK3 and overexpression of miR-125a markedly promoted the migratory and invasive abilities of GC cells. Additionally, the protein and mRNA expression levels of metastasis-related genes, including N-cadherin, Vimentin, MMP2 and MMP9, were markedly decreased in the DKK3 and miR-125a inhibitor groups compared to their control groups and markedly increased in the DKK3 shRNA and miR-125a groups compared with the control group. Finally, a dual luciferase reporter assay and ChIP assay showed that E2F3 binds to the miR-125a promoter and that the DKK3 mRNA 3′UTR is a direct target of miR-125a. Furthermore, analysis of Kaplan–Meier curves also confirmed the regulatory role of E2F3 on miR-125a. Additionally, BGC823 cells transfected with E2F3 plasmids and shRNA downregulated and upregulated the expression of DKK3, respectively.

Conclusion

Our results suggested that E2F3 might play a tumour-promoting role in the metastasis and progression of GC by regulating the miR-125a/DKK3 axis.
Literature
1.
go back to reference Cavatorta O, Scida S, Miraglia C, et al. Epidemiology of gastric cancer and risk factors. Acta Biomed. 2018;89(8-S):82–7.PubMed Cavatorta O, Scida S, Miraglia C, et al. Epidemiology of gastric cancer and risk factors. Acta Biomed. 2018;89(8-S):82–7.PubMed
2.
go back to reference Venerito M, Vasapolli R, Rokkas T, et al. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23(Suppl 1):e12518.CrossRef Venerito M, Vasapolli R, Rokkas T, et al. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23(Suppl 1):e12518.CrossRef
3.
go back to reference Venerito M, Nardone G, Selgrad M, et al. Gastric cancer–epidemiologic and clinical aspects. Helicobacter. 2014;19(Suppl 1):32–7.CrossRef Venerito M, Nardone G, Selgrad M, et al. Gastric cancer–epidemiologic and clinical aspects. Helicobacter. 2014;19(Suppl 1):32–7.CrossRef
4.
go back to reference Kinoshita T, Kaito A. Current status and future perspectives of laparoscopic radical surgery for advanced gastric cancer. Transl Gastroenterol Hepatol. 2017;2:43.CrossRef Kinoshita T, Kaito A. Current status and future perspectives of laparoscopic radical surgery for advanced gastric cancer. Transl Gastroenterol Hepatol. 2017;2:43.CrossRef
5.
go back to reference Zhou J, Shen J, Seifer BJ, et al. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget. 2017;8(18):30477–94.CrossRef Zhou J, Shen J, Seifer BJ, et al. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget. 2017;8(18):30477–94.CrossRef
6.
go back to reference Jiang ZW, Li JS. Current status and future perspectives of robotic surgery and laparoscopic surgery for gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(8):776–7.PubMed Jiang ZW, Li JS. Current status and future perspectives of robotic surgery and laparoscopic surgery for gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(8):776–7.PubMed
7.
go back to reference Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230–6.CrossRef Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230–6.CrossRef
8.
go back to reference Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700–13.CrossRef Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700–13.CrossRef
9.
go back to reference Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol. 2014;20(19):5694–9.CrossRef Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol. 2014;20(19):5694–9.CrossRef
10.
go back to reference Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432–9.CrossRef Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432–9.CrossRef
11.
go back to reference Ge F, Wang C, Wang W, et al. MicroRNA-31 inhibits tumor invasion and metastasis by targeting RhoA in human gastric cancer. Oncol Rep. 2017;38(2):1133–9.CrossRef Ge F, Wang C, Wang W, et al. MicroRNA-31 inhibits tumor invasion and metastasis by targeting RhoA in human gastric cancer. Oncol Rep. 2017;38(2):1133–9.CrossRef
12.
go back to reference Yu H, Zhang J, Wen Q, et al. MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer. Exp Ther Med. 2018;16(4):3249–55.PubMedPubMedCentral Yu H, Zhang J, Wen Q, et al. MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer. Exp Ther Med. 2018;16(4):3249–55.PubMedPubMedCentral
13.
go back to reference Shi J, Gong L, Chen L, et al. MiR-618 suppresses metastasis in gastric cancer by downregulating the expression of TGF-beta2. Anat Rec. 2019;302(6):931–40. Shi J, Gong L, Chen L, et al. MiR-618 suppresses metastasis in gastric cancer by downregulating the expression of TGF-beta2. Anat Rec. 2019;302(6):931–40.
14.
go back to reference Wang F, Sun GP, Zou YF, et al. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark. 2012;11(6):259–67.CrossRef Wang F, Sun GP, Zou YF, et al. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark. 2012;11(6):259–67.CrossRef
15.
go back to reference Wang Y, Wang B, Xiao S, et al. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90. J Cell Biochem. 2019;120(3):3046–55.CrossRef Wang Y, Wang B, Xiao S, et al. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90. J Cell Biochem. 2019;120(3):3046–55.CrossRef
16.
go back to reference Yang X, Qiu J, Kang H, et al. miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA. Cancer Manag Res. 2018;10:5839–53.CrossRef Yang X, Qiu J, Kang H, et al. miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA. Cancer Manag Res. 2018;10:5839–53.CrossRef
17.
go back to reference Zhang Y, Zhang D, Lv J, et al. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. Biomed Pharmacother. 2018;108:1039–47.CrossRef Zhang Y, Zhang D, Lv J, et al. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. Biomed Pharmacother. 2018;108:1039–47.CrossRef
18.
go back to reference Yang L, Zhang S, Guo K, et al. miR-125a restrains cell migration and invasion by targeting STAT3 in gastric cancer cells. Onco Targets Ther. 2019;12:205–15.CrossRef Yang L, Zhang S, Guo K, et al. miR-125a restrains cell migration and invasion by targeting STAT3 in gastric cancer cells. Onco Targets Ther. 2019;12:205–15.CrossRef
19.
go back to reference Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17(9):2725–33.CrossRef Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17(9):2725–33.CrossRef
20.
go back to reference Manicum T, Ni F, Ye Y, et al. Prognostic values of E2F mRNA expression in human gastric cancer. Biosci Rep. 2018;38(6):1–14.CrossRef Manicum T, Ni F, Ye Y, et al. Prognostic values of E2F mRNA expression in human gastric cancer. Biosci Rep. 2018;38(6):1–14.CrossRef
21.
go back to reference Hamzehzadeh L, Caraglia M, Atkin SL, et al. Dickkopf homolog 3 (DKK3): a candidate for detection and treatment of cancers? J Cell Physiol. 2018;233(6):4595–605.CrossRef Hamzehzadeh L, Caraglia M, Atkin SL, et al. Dickkopf homolog 3 (DKK3): a candidate for detection and treatment of cancers? J Cell Physiol. 2018;233(6):4595–605.CrossRef
22.
go back to reference Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26(4):243–55.CrossRef Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26(4):243–55.CrossRef
23.
go back to reference Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: east versus west. J Surg Oncol. 2017;115(5):603–14.CrossRef Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: east versus west. J Surg Oncol. 2017;115(5):603–14.CrossRef
24.
go back to reference Suh YS, Yang HK. Screening and early detection of gastric cancer: east versus west. Surg Clin North Am. 2015;95(5):1053–66.CrossRef Suh YS, Yang HK. Screening and early detection of gastric cancer: east versus west. Surg Clin North Am. 2015;95(5):1053–66.CrossRef
25.
go back to reference Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 2012;1825(1):18–28.PubMed Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 2012;1825(1):18–28.PubMed
26.
go back to reference Oudin MJ, Weaver VM. Physical and chemical gradients in the tumor microenvironment regulate tumor cell invasion, migration, and metastasis. Cold Spring Harb Symp Quant Biol. 2016;81:189–205.CrossRef Oudin MJ, Weaver VM. Physical and chemical gradients in the tumor microenvironment regulate tumor cell invasion, migration, and metastasis. Cold Spring Harb Symp Quant Biol. 2016;81:189–205.CrossRef
27.
go back to reference van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14(2):121–34.CrossRef van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14(2):121–34.CrossRef
28.
go back to reference Kourtidis A, Lu R, Pence LJ, et al. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358(1):78–85.CrossRef Kourtidis A, Lu R, Pence LJ, et al. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358(1):78–85.CrossRef
29.
go back to reference Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–46.CrossRef Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–46.CrossRef
30.
go back to reference Zhong Y, Lu YT, Sun Y, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin Drug Discov. 2018;13(1):75–87.CrossRef Zhong Y, Lu YT, Sun Y, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin Drug Discov. 2018;13(1):75–87.CrossRef
31.
go back to reference Suzuki T, Yasui W, Yokozaki H, et al. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999;81(4):535–8.CrossRef Suzuki T, Yasui W, Yokozaki H, et al. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999;81(4):535–8.CrossRef
32.
go back to reference Yin D, Wu W, Li M, et al. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer. 2013;20(4):507–14.CrossRef Yin D, Wu W, Li M, et al. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer. 2013;20(4):507–14.CrossRef
33.
go back to reference Chen G, Zheng H. The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis. Cancer Biomark. 2018;23(3):323–31.CrossRef Chen G, Zheng H. The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis. Cancer Biomark. 2018;23(3):323–31.CrossRef
34.
go back to reference Ferrari N, Ranftl R, Chicherova I, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019;10(1):130–45.CrossRef Ferrari N, Ranftl R, Chicherova I, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019;10(1):130–45.CrossRef
35.
go back to reference Yoda Y, Takeshima H, Niwa T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18(1):65–76.CrossRef Yoda Y, Takeshima H, Niwa T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18(1):65–76.CrossRef
36.
go back to reference Gao Y, Feng B, Lu L, et al. MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget. 2017;8(36):60624–39.CrossRef Gao Y, Feng B, Lu L, et al. MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget. 2017;8(36):60624–39.CrossRef
37.
go back to reference Ciafre SA, Galardi S. microRNAs and RNA-binding proteins: a complex network of interactions and reciprocal regulations in cancer. RNA Biol. 2013;10(6):935–42.CrossRef Ciafre SA, Galardi S. microRNAs and RNA-binding proteins: a complex network of interactions and reciprocal regulations in cancer. RNA Biol. 2013;10(6):935–42.CrossRef
Metadata
Title
The E2F3/miR-125a/DKK3 regulatory axis promotes the development and progression of gastric cancer
Authors
Yihua Pei
Zhiteng Tang
Minjing Cai
Qin Yao
Bozhen Xie
Xin Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0930-y

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine